^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gemcitabine

    i
    Other names: dFdC, LY 188011, LY188011, LY-188011
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1m
    Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study. (PubMed, Front Immunol)
    Adjuvant ADC+ICI showed comparable short-term OS and directionally favorable DFS/PFS trends versus GC, with a distinct toxicity profile. These findings are hypothesis-generating and require prospective validation.
    Clinical • Observational data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cisplatin • gemcitabine • Aidixi (disitamab vedotin)
    1m
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University of Maryland, Baltimore | Trial completion date: Dec 2027 --> Dec 2026
    Trial completion date
    |
    gemcitabine
    1m
    A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (clinicaltrials.gov)
    P1/2, N=222, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • RAS mutation
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    1m
    Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients (clinicaltrials.gov)
    P1, N=12, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting | Trial completion date: Feb 2026 --> Feb 2027
    Enrollment open • Trial completion date
    |
    cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr)
    1m
    Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date • Platinum sensitive
    |
    carboplatin • gemcitabine • berzosertib (M6620)
    1m
    The Role of Hypoxia-Regulated MicroRNAs (Hypoxamirs) in Tumor-Associated Macrophage Polarization: A Systematic Review. (PubMed, Cureus)
    These coordinated pathways drive an "angiogenic switch," facilitate "metabolic migration," and induce significant resistance to chemotherapies, including gemcitabine and temozolomide. The hypoxamir-TAM axis is a fundamental driver of immune evasion and therapeutic failure. Targeting this dual-axis framework offers a viable strategy for restoring anti-tumor immunity, while circulating hypoxamirs represent high-value liquid biopsy biomarkers for real-time TME monitoring.
    Review • Journal
    |
    PTEN (Phosphatase and tensin homolog) • IRF1 (Interferon Regulatory Factor 1) • MIR210 (MicroRNA 210) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • MIR30C
    |
    gemcitabine • temozolomide
    1m
    [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=22, Not yet recruiting, University of Washington
    New P2 trial
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    1m
    Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation. (PubMed, Med)
    Chemoimmunotherapy is the reference first-line regimen for biomarker-unselected advanced cholangiocarcinoma. Early comprehensive genomic profiling is essential to enable timely, matched targeted therapy and maximize population-level benefit.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    MSI-H/dMMR • IDH1 mutation • EGFR positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • oxaliplatin • Tibsovo (ivosidenib) • leucovorin calcium
    1m
    Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. (PubMed, Cancer Genomics Proteomics)
    Our integrated transcriptomic and functional analyses support DOT1L as a clinically relevant epigenetic factor associated with the response of CCA to gemcitabine and suggest a mechanistic link involving S-phase regulation and apoptosis. DOT1L may serve as a candidate biomarker and a potential target to improve gemcitabine efficacy in CCA.
    Journal
    |
    CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
    |
    gemcitabine
    1m
    Patient-derived organoids as a predictive platform for drug sensitivity in bladder cancer. (PubMed, Sci Rep)
    Functional drug screening of early-passage PDOs revealed heterogeneous responses to standard-of-care (SOC) agents, cisplatin and gemcitabine, as well as the EGFR/HER2 inhibitor lapatinib. These results demonstrate that BC PDOs faithfully model tumor heterogeneity and offer a robust platform for individualized drug response profiling. Our findings support the utility of PDOs for preclinical drug evaluation and precision oncology, particularly in identifying effective combination therapies such as lapatinib-enhanced chemotherapy.
    Journal
    |
    GATA3 (GATA binding protein 3) • LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    cisplatin • gemcitabine • lapatinib
    1m
    GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical